- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 5.75 Å
- Oligo State
- hetero-3-3-3-3-3-mer
- Ligands
- 1 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 14 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 6 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA.3: 5 residues within 4Å:- Chain D: V.104, N.118, S.120, Y.135, D.290
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.4: 11 residues within 4Å:- Chain D: E.181, P.182, V.224, L.231, N.232, N.346, G.348, C.413, V.414, S.415
- Ligands: NAG-NAG.8
1 PLIP interactions:1 interactions with chain D- Hydrogen bonds: D:G.348
NAG-NAG-BMA.13: 5 residues within 4Å:- Chain I: V.104, N.118, S.120, Y.135, D.290
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.14: 7 residues within 4Å:- Chain I: E.181, P.182, L.231, N.232, G.348, S.415
- Ligands: NAG-NAG.18
1 PLIP interactions:1 interactions with chain I- Hydrogen bonds: I:G.348
NAG-NAG-BMA.21: 3 residues within 4Å:- Chain N: V.104, N.118, Y.135
1 PLIP interactions:1 interactions with chain N- Hydrogen bonds: N:Y.135
NAG-NAG-BMA.22: 10 residues within 4Å:- Chain N: E.181, L.231, N.232, F.345, G.348, R.412, C.413, V.414, S.415
- Ligands: NAG-NAG.26
No protein-ligand interaction detected (PLIP)- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN-MAN.7: 19 residues within 4Å:- Chain C: S.25, Q.47, P.61, D.62, I.63
- Chain D: T.267, R.296, H.299, N.301, S.381, R.412
- Chain E: G.101, Q.102, R.103, I.104, Y.105, G.106, V.107, V.108
3 PLIP interactions:2 interactions with chain D, 1 interactions with chain E- Hydrogen bonds: D:R.296, D:R.296, E:V.108
NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN-MAN.17: 18 residues within 4Å:- Chain H: S.25, Q.47, P.61, D.62, I.63
- Chain I: T.267, R.296, H.299, N.301, R.412
- Chain J: G.101, Q.102, R.103, I.104, G.106, V.107, V.108, Y.116
3 PLIP interactions:2 interactions with chain I, 1 interactions with chain J- Hydrogen bonds: I:R.296, I:R.296, J:V.108
NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN-MAN.25: 20 residues within 4Å:- Chain M: S.25, R.26, N.45, Q.47, P.61, D.62, I.63
- Chain N: T.267, R.296, H.299, N.301, S.381, R.412
- Chain O: G.101, Q.102, R.103, I.104, G.106, V.107, V.108
3 PLIP interactions:2 interactions with chain N, 1 interactions with chain O- Hydrogen bonds: N:R.296, N:R.296, O:V.108
- 2 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN.10: 12 residues within 4Å:- Chain F: S.17
- Chain G: N.30, F.31, H.33, S.52, Y.54, R.110, G.112, S.113, T.115, H.249
- Chain I: N.58
3 PLIP interactions:3 interactions with chain G- Hydrogen bonds: G:T.115, G:T.115, G:G.112, G:R.110, G:R.110
- Hydrophobic interactions: G:R.110
NAG-NAG-BMA-MAN.19: 15 residues within 4Å:- Chain K: S.17
- Chain L: N.30, F.31, Y.32, H.33, S.52, Y.54, R.110, D.111, G.112, S.113, T.115, W.116, H.249
- Chain N: N.58
2 PLIP interactions:2 interactions with chain L- Hydrogen bonds: L:G.112, L:T.115, L:W.116, L:H.249, L:H.33, L:T.115
- 31 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.27: 2 residues within 4Å:- Chain A: N.100, S.102
Ligand excluded by PLIPNAG.28: 8 residues within 4Å:- Chain A: R.106, E.110, N.114, M.115, Q.119
- Chain B: Q.1, Y.32, Y.119
Ligand excluded by PLIPNAG.29: 3 residues within 4Å:- Chain A: E.123, N.126, Y.127
Ligand excluded by PLIPNAG.30: 4 residues within 4Å:- Chain D: Q.100, S.120, F.121, N.122
Ligand excluded by PLIPNAG.31: 2 residues within 4Å:- Chain D: N.167
- Chain N: R.278
Ligand excluded by PLIPNAG.32: 5 residues within 4Å:- Chain D: N.204, T.206, S.244, E.245, I.247
Ligand excluded by PLIPNAG.33: 3 residues within 4Å:- Chain D: N.246, T.248, N.249
Ligand excluded by PLIPNAG.34: 1 residues within 4Å:- Chain D: N.324
Ligand excluded by PLIPNAG.35: 3 residues within 4Å:- Chain D: N.355, S.357
- Ligands: NAG.36
Ligand excluded by PLIPNAG.36: 3 residues within 4Å:- Chain D: G.358, N.361
- Ligands: NAG.35
Ligand excluded by PLIPNAG.37: 6 residues within 4Å:- Chain D: C.101, T.102, N.103, D.110, R.113, K.117
Ligand excluded by PLIPNAG.38: 1 residues within 4Å:- Chain F: N.100
Ligand excluded by PLIPNAG.39: 9 residues within 4Å:- Chain F: R.106, D.113, N.114
- Chain G: Q.1, Y.32, K.106, L.108, L.109, R.110
Ligand excluded by PLIPNAG.40: 3 residues within 4Å:- Chain F: E.123, N.126, Y.127
Ligand excluded by PLIPNAG.41: 4 residues within 4Å:- Chain I: Q.100, S.120, F.121, N.122
Ligand excluded by PLIPNAG.42: 4 residues within 4Å:- Chain I: N.204, S.244, E.245, I.247
Ligand excluded by PLIPNAG.43: 3 residues within 4Å:- Chain I: N.246, T.248, N.249
Ligand excluded by PLIPNAG.44: 1 residues within 4Å:- Chain I: N.324
Ligand excluded by PLIPNAG.45: 3 residues within 4Å:- Chain I: N.355, S.357
- Ligands: NAG.46
Ligand excluded by PLIPNAG.46: 3 residues within 4Å:- Chain I: G.358, N.361
- Ligands: NAG.45
Ligand excluded by PLIPNAG.47: 2 residues within 4Å:- Chain K: N.100, S.102
Ligand excluded by PLIPNAG.48: 10 residues within 4Å:- Chain K: R.106, E.110, D.113, N.114
- Chain L: Q.1, Y.32, K.106, L.108, L.109, R.110
Ligand excluded by PLIPNAG.49: 3 residues within 4Å:- Chain K: E.123, N.126, Y.127
Ligand excluded by PLIPNAG.50: 5 residues within 4Å:- Chain N: Q.100, S.120, F.121, N.122, K.133
Ligand excluded by PLIPNAG.51: 1 residues within 4Å:- Chain N: N.167
Ligand excluded by PLIPNAG.52: 5 residues within 4Å:- Chain N: N.204, T.206, S.244, E.245, I.247
Ligand excluded by PLIPNAG.53: 3 residues within 4Å:- Chain N: N.246, T.248, N.249
Ligand excluded by PLIPNAG.54: 1 residues within 4Å:- Chain N: N.324
Ligand excluded by PLIPNAG.55: 3 residues within 4Å:- Chain N: N.355, S.357
- Ligands: NAG.56
Ligand excluded by PLIPNAG.56: 2 residues within 4Å:- Chain N: N.361
- Ligands: NAG.55
Ligand excluded by PLIPNAG.57: 6 residues within 4Å:- Chain N: C.101, T.102, N.103, D.110, R.113, K.117
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Del Moral-Sanchez, I. et al., Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines. Npj Vaccines (2024)
- Release Date
- 2024-04-17
- Peptides
- Envelope glycoprotein gp41: AFK
35O22 scFv: BGL
PGT124 light chain: CHM
Envelope glycoprotein gp120: DIN
PGT124 heavy chain: EJO - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
BF
HK
aB
DG
LL
bC
CH
PM
cD
GI
RN
eE
OJ
SO
f
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 5.75 Å
- Oligo State
- hetero-3-3-3-3-3-mer
- Ligands
- 1 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 14 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 6 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 2 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 31 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Del Moral-Sanchez, I. et al., Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines. Npj Vaccines (2024)
- Release Date
- 2024-04-17
- Peptides
- Envelope glycoprotein gp41: AFK
35O22 scFv: BGL
PGT124 light chain: CHM
Envelope glycoprotein gp120: DIN
PGT124 heavy chain: EJO - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
BF
HK
aB
DG
LL
bC
CH
PM
cD
GI
RN
eE
OJ
SO
f